@article{86a6b59a280743a3911160e4af71f820,
title = "Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism",
abstract = "Background: Studies of copy number variation (CNV) have characterized loci and molecular pathways in a range of neuropsychiatric conditions. We analyzed rare CNVs in Tourette syndrome (TS) to identify novel risk regions and relevant pathways, to evaluate burden of structural variation in cases versus controls, and to assess overlap of identified variations with those in other neuropsychiatric syndromes. Methods: We conducted a case-control study of 460 individuals with TS, including 148 parent-child trios and 1131 controls. CNV analysis was undertaken using 370 K to 1 M probe arrays, and genotyping data were used to match cases and controls for ancestry. CNVs present in < 1% of the population were evaluated. Results: While there was no significant increase in the number of de novo or transmitted rare CNVs in cases versus controls, pathway analysis using multiple algorithms showed enrichment of genes within histamine receptor (subtypes 1 and 2) signaling pathways (p = 5.8 × 10 -4 - 1.6 × 10 -2), as well as axon guidance, cell adhesion, nervous system development, and synaptic structure and function processes. Genes mapping within rare CNVs in TS showed significant overlap with those previously identified in autism spectrum disorders but not intellectual disability or schizophrenia. Three large, likely pathogenic, de novo events were identified, including one disrupting multiple gamma-aminobutyric acid receptor genes. Conclusions: We identify further evidence supporting recent findings regarding the involvement of histaminergic and gamma-aminobutyric acidergic mechanisms in the etiology of TS and show an overlap of rare CNVs in TS and autism spectrum disorders.",
keywords = "Autism, CNV, GABA, Tourette syndrome, copy number variation, histamine",
author = "Fernandez, {Thomas V.} and Sanders, {Stephan J.} and Yurkiewicz, {Ilana R.} and Ercan-Sencicek, {A. Gulhan} and Kim, {Young Shin} and Fishman, {Daniel O.} and Raubeson, {Melanie J.} and Youeun Song and Katsuhito Yasuno and Ho, {Winson S.C.} and Kaya Bilguvar and Joseph Glessner and Chu, {Su Hee} and Leckman, {James F.} and King, {Robert A.} and Gilbert, {Donald L.} and Heiman, {Gary A.} and Tischfield, {Jay A.} and Hoekstra, {Pieter J.} and Bernie Devlin and Hakon Hakonarson and Mane, {Shrikant M.} and Murat Gnel and State, {Matthew W.}",
note = "Funding Information: Dr. Leckman has received support from the following: NIH (salary and research funding), Tourette Syndrome Association (research funding), Talecris Biotherapeutics (research funding), Klingenstein Third Generation Foundation (medical student fellowship program), C8Sciences (equity interest), John Wiley and Sons (book royalties), McGraw Hill (book royalties), Oxford University Press (book royalties). Dr. Gilbert has received research funding as a site investigator for pharmaceutical studies sponsored by Psyadon Pharmaceuticals and Otsuka Pharmaceuticals. He has received honoraria from the Tourette Syndrome Association/Centers for Disease Control and Prevention, the Movement Disorder Society, the American Academy of Neurology, and the American Academy of Pediatrics; serves on the medical advisory board for the Tourette Syndrome Association; writes board review questions for PREP SA (American Academy of Pediatrics); and has received research support from the NIH (National Institute of Mental Health R01 MH078160 , National Institute of Mental Health R01 MH08185 , and National Institute for Neurological Disease and Stroke NS056276 ) and from the Cincinnati Children's Hospital Research Foundation, the University of Cincinnati, and the Tourette Syndrome Association. Dr. Hoekstra has received research funding from National (the Netherlands Organization for Scientific Research and the Netherlands Organization for Health Research and Development) and European Science Foundations (European Union Seventh Framework Programme) over the last 2 years. He also received honoraria from Desitin, Lilly, and Shire. Dr. State holds a patent with Yale University regarding the contribution of specific rare mutations in the gene CNTNAP2 and autism spectrum disorders. Drs. Fernandez, Sanders, Ercan-Sencicek, Kim, Song, Yasuno, Ho, Bilguvar, Glessner, Chu, King, Heiman, Tischfield, Devlin, Hakonarson, Mane, and Gunel; Ms. Yurkiewicz and Raubeson; and Mr. Fishman have no biomedical financial interests or potential conflicts of interest to declare. Funding Information: This study was funded by National Institutes of Health (NIH) Grants: R01MH092289 (MWS), R01MH092293 (GAH and JAT), R01MH092520 (DLG), R01NS056276 (MWS), R01MH061940 (JFL), K05MH076273 (JFL), R25MH077823 (JFL), UL1RR024139 (SMM), U24NS051869 (SMM). Additional funding was provided by the Shepherd Foundation (MWS), the Overlook International Fund (MWS), the Yale Program on Neurogenetics (MG, MWS), and the New Jersey Center for Tourette Syndrome & Associated Disorders (through New Jersey Department of Health and Senior Services: 09-1839-FS-N-0) (GAH and JAT). ",
year = "2012",
month = mar,
day = "1",
doi = "10.1016/j.biopsych.2011.09.034",
language = "English (US)",
volume = "71",
pages = "392--402",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "5",
}